公开(公告)号：US20110166838A1

公开(公告)日：2011-07-07

申请号：US12999522

申请日：2009-06-16

Applicant: Mathias Gehrmann ,  Ralf Kronenwett ,  Udo Stropp ,  Christian Von Törne ,  Karsten Weber

Inventor： Mathias Gehrmann ,  Ralf Kronenwett ,  Udo Stropp ,  Christian Von Törne ,  Karsten Weber

IPC: G06F7/60

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G16B20/00 ,  G16B25/00 ,  G16B40/00

Abstract: The invention relates to methods for predicting an outcome of cancer in a patient suffering from cancer, said patient having been previously diagnosed as node positive and treated with cytotoxic chemotherapy, said method comprising determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CAl2, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF; ABCB1, ABCG2, ADAM15, AKR1C1, AKR1C3, AKT1, BANF1, BCL2, BIRC5, BRMS1, CASP10, CCNE2, CENPJ, CHPT1, EGFR, CTTN, ERBB3, ERBB4, FBLN1, FIP1L1, FLT1, FLT4, FNTA, GATA3, GSTP1, Herstatin, IGF1R, IGHM, KDR, KIT, CKRT5, SLC39A6, MAPK3, MAPT, MKI67, MMP7, MTA1, FRAP1, MUC1, MYC, NCOA3, NFIB, OLFM1, TP53, PCNA, PI3K, PPERLD1, RAB31, RAD54B, RAF1, SCUBE2, STAU, TINF2, TMSL8, VGLL1, TRA@, TUBA1, TUBB, TUBB2A.

Abstract translation: 本发明涉及用于预测患有癌症的患者的癌症结果的方法，所述患者先前被诊断为淋巴结阳性并用细胞毒性化疗治疗，所述方法包括在来自所述患者的生物样品中确定多个表达水平 选自ACTG1，CA2，CALM2，CCND1，CHPT1，CLEC2B，CTSB，CXCL13，DCN，DHRS2，EIF4B，ERBB2，ESR1，FBXO28，GABRP，GAPDH，H2AFZ，IGFBP3，IGHG1，IGKC，KCTD3， KIAA0101，KRT17，MLPH，MMP1，NAT1，NEK2，NR2F2，OAZ1，PCNA，PDLIM5，PGR，PPIA，PRC1，RACGAP1，RPL37A，SOX4，TOP2A，UBE2C和VEGF; ABCB1，ABCG2，ADAM15，AKR1C1，AKR1C3，AKT1，BANF1，BCL2，BIRC5，BRMS1，CASP10，CCNE2，CENPJ，CHPT1，EGFR，CTTN，ERBB3，ERBB4，FBLN1，FIP1L1，FLT1，FLT4，FNTA，GATA3，GSTP1， Herbatin，IGF1R，IGHM，KDR，KIT，CKRT5，SLC39A6，MAPK3，MAPT，MKI67，MMP7，MTA1，FRAP1，MUC1，MYC，NCOA3，NFIB，OLFM1，TP53，PCNA，PI3K，PPERLD1，RAB31，RAD54B，RAF1， SCUBE2，STAU，TINF2，TMSL8，VGLL1，TRA @，TUBA1，TUBB，TUBB2A。

公开(公告)号：US5849893A

公开(公告)日：1998-12-15

申请号：US719048

申请日：1996-09-24

Applicant: Antonius Lobberding ,  Burkhard Mielke ,  Christoph Schwemler ,  Eckhard Schwenner ,  Udo Stropp ,  Wolfgang Springer ,  Axel Kretschmer ,  Thorsten Potter

Inventor： Antonius Lobberding ,  Burkhard Mielke ,  Christoph Schwemler ,  Eckhard Schwenner ,  Udo Stropp ,  Wolfgang Springer ,  Axel Kretschmer ,  Thorsten Potter

IPC: C12N15/09 ,  A61K31/40 ,  A61K31/495 ,  A61K31/505 ,  A61K38/00 ,  A61K38/10 ,  A61P31/12 ,  C07C271/22 ,  C07C309/66 ,  C07D207/16 ,  C07D239/46 ,  C07D239/47 ,  C07D239/54 ,  C07D403/04 ,  C07D403/12 ,  C07D473/18 ,  C07D473/30 ,  C07D473/34 ,  C07K5/00 ,  C07K5/062 ,  C07K5/078 ,  C07K5/097 ,  C07K5/117 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07H21/04

CPC classification number: C07D239/47 ,  C07C309/66 ,  C07D239/54 ,  C07D403/04 ,  C07K14/003 ,  C07K7/06 ,  C07K7/08 ,  A61K38/00

Abstract: The invention relates to nucleic acid-binding oligomers possessing C-branching of the general formula (I) ##STR1## and to the corresponding monomers, whose radicals have the meaning given in the description, and to their use as medicaments or diagnostic aids.

Abstract translation: 本发明涉及具有通式（I）C支化的核酸结合低聚物（I）和相应的单体，其基团具有说明书中给出的含义，以及它们作为药物或诊断用途 艾滋病。

公开(公告)号：US5623049A

公开(公告)日：1997-04-22

申请号：US300884

申请日：1994-09-06

Applicant: Antonius L obberding ,  Burkhard Mielke ,  Christoph Schwemler ,  Eckhard Schwenner ,  Udo Stropp ,  Wolfgang Springer ,  Axel Kretschmer ,  Thorsten P otter

Inventor： Antonius L obberding ,  Burkhard Mielke ,  Christoph Schwemler ,  Eckhard Schwenner ,  Udo Stropp ,  Wolfgang Springer ,  Axel Kretschmer ,  Thorsten P otter

IPC: C07D239/47 ,  A61K31/195 ,  A61K31/40 ,  A61K31/401 ,  A61K38/00 ,  A61K38/10 ,  A61P31/12 ,  C07D239/54 ,  C07D403/06 ,  C07D403/12 ,  C07D473/18 ,  C07D473/30 ,  C07D473/34 ,  C07K5/00 ,  C07K5/06 ,  C07K5/062 ,  C07K7/06 ,  C07K14/00 ,  C07K19/00 ,  C07K7/00 ,  C07D239/00 ,  C07H5/04 ,  C07H21/04

CPC classification number: C07D239/54 ,  C07D403/06 ,  C07D473/18 ,  C07D473/30 ,  C07D473/34 ,  C07K14/003 ,  C07K5/06026 ,  A61K38/00

Abstract: The invention relates to nucleic acid-binding oligomers possessing N-branching of the general formula (I), ##STR1## and their monomers, where the individual radicals have the meaning given in the description, and to their use as medicaments or as aids in diagnostics.

Abstract translation: 本发明涉及具有通式（I）的N-支化的核酸结合寡聚体及其单体，其中各个基团具有说明书中给出的含义，以及它们作为药物或 作为诊断的辅助工具。

公开(公告)号：US20110172928A1

公开(公告)日：2011-07-14

申请号：US12999406

申请日：2009-06-16

Applicant: Mathias Gehrmann ,  Udo Stropp ,  Karsten Weber ,  Christian Von Törne ,  Marcus Schmidt

Inventor： Mathias Gehrmann ,  Udo Stropp ,  Karsten Weber ,  Christian Von Törne ,  Marcus Schmidt

IPC: G06F19/00

CPC classification number: C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  G16B20/00 ,  G16B25/00 ,  G16B40/00

Abstract: The present invention relates to methods for prediction of an outcome of neoplastic disease or cancer. More specifically, the present invention relates to a method for the prediction of breast cancer by determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CA12, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF.

Abstract translation: 本发明涉及用于预测肿瘤性疾病或癌症的结果的方法。 更具体地，本发明涉及通过在来自所述患者的生物样品中测定多种选自ACTG1，CA12，CALM2，CCND1，CHPT1，CLEC2B的多种基因的表达水平来预测乳腺癌的方法 ，CTSB，CXCL13，DCN，DHRS2，EIF4B，ERBB2，ESR1，FBXO28，GABRP，GAPDH，H2AFZ，IGFBP3，IGHG1，IGKC，KCTD3，KIAA0101，KRT17，MLPH，MMP1，NAT1，NEK2，NR2F2，OAZ1，PCNA，PDLIM5 ，PGR，PPIA，PRC1，RACGAP1，RPL37A，SOX4，TOP2A，UBE2C和VEGF。

公开(公告)号：US20110166845A1

公开(公告)日：2011-07-07

申请号：US13061797

申请日：2009-07-16

Applicant: Christian Von Törne ,  Mareike Assink ,  Udo Stropp

Inventor： Christian Von Törne ,  Mareike Assink ,  Udo Stropp

IPC: G06G7/58

CPC classification number: C12Q1/6851 ,  G16B40/00 ,  C12Q2537/165

Abstract: The invention relates to a method for the quality assessment of nucleic acid amplification reactions which is based on a mathematical approach for the quality assessment of complete nucleic acid amplification reactions and comprises the following steps: a) Carrying out an amplification reaction for at least one nucleic acid target molecule, b)Collecting time-related data reflecting the course of the amplification reaction, c) Fitting these time-related data with a growth model equation comprising at least one parameter, d) Obtaining, from said fitting process, at least one value for the at least one parameter.

Abstract translation: 本发明涉及一种核酸扩增反应质量评估方法，该方法基于完整核酸扩增反应的质量评估的数学方法，包括以下步骤：a）对至少一个核酸进行扩增反应 酸性靶分子，b）收集反映扩增反应过程的时间相关数据，c）使用包含至少一个参数的生长模型方程拟合这些时间相关数据，d）从所述拟合过程获得至少一个 至少一个参数的值。

公开(公告)号：US20090197246A1

公开(公告)日：2009-08-06

申请号：US10585474

申请日：2005-01-07

Applicant: Udo Stropp

Inventor： Udo Stropp

IPC: C12Q1/68 ,  C07H21/04

CPC classification number: C12N9/1007 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/16 ,  C12Q2600/172

Abstract: Haplotypes and polymorphisms of thiopurine S-methyltransferase (TPMT) are described that are linked to TPMT deficiencies which can cause potentially fatal toxicity when patients are treated with thiopurines like mercaptopurine, azathioprine, or thioguanine. The mutant alleles as well as PCR fragments, kits and methods for assaying the TPMT genotype of individual patients are disclosed. Furthermore, algorithms are disclosed that combine the genotypes of a set of single nucleotide polymorphisms to haplotypes that give a distinct information about the TPMT phenotype.

Abstract translation: 描述了硫代嘌呤S-甲基转移酶（TPMT）的单倍型和多态性，其与TPMT缺陷相关，当患者用硫嘌呤如巯基嘌呤，硫唑嘌呤或硫鸟嘌呤治疗时，可引起潜在的致命毒性。 公开了突变等位基因以及用于测定个体患者的TPMT基因型的PCR片段，试剂盒和方法。 此外，公开了将一组单核苷酸多态性的基因型与单倍型组合的算法，其给出了关于TPMT表型的不同信息。

公开(公告)号：US20070128597A1

公开(公告)日：2007-06-07

申请号：US10525278

申请日：2003-08-18

Applicant: Stephan Schwers ,  Harald Kallabis ,  Udo Stropp

Inventor： Stephan Schwers ,  Harald Kallabis ,  Udo Stropp

IPC: C12Q1/68 ,  C07H21/04 ,  C12P21/06 ,  C07K14/705

CPC classification number: C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/6893 ,  G01N2800/32 ,  G01N2800/52

Abstract: Single Nucleotide Polymorphisms sensitively predicting Advserse Drug Reactions (ADR) and Drug Efficacy Abs tract. The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising: SEQ ID 1-168 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence.

Abstract translation: 单核苷酸多态性灵敏预测Advancese药物反应（ADR）和药物功效性Abs。 本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否有获得不良药物反应风险的抗体，还是人类受试者是高反应者还是低反应者 他汀类药物或代谢物。 本发明提供了进一步的诊断方法和试剂盒，包括确定人受试者是否处于心血管疾病风险的抗体。 本发明还提供了多态序列和其他基因。 本发明还涉及编码可用于鉴定治疗剂并用于制备治疗心血管疾病或影响药物应答的药物的方法中的表型相关（PA）基因多肽的分离的多核苷酸，所述多核苷酸选自SEQ ID NO： ID 1-168，其具有如包含在功能性周围的序列部分中所示的等位基因变异，如PA基因多肽的全长cDNA并具有或不具有PA基因启动子序列。

公开(公告)号：US20060204962A1

公开(公告)日：2006-09-14

申请号：US10544049

申请日：2004-01-31

Applicant: Udo Stropp ,  Stephan Schwers ,  Harald Kallabis ,  Gerd Schmitz

Inventor： Udo Stropp ,  Stephan Schwers ,  Harald Kallabis ,  Gerd Schmitz

IPC: C12Q1/68 ,  C07H21/04 ,  C12P21/06 ,  C07K14/47

CPC classification number: C07K14/4702 ,  A61K38/00 ,  C07K14/7156 ,  C07K14/8132 ,  C12Q1/6876 ,  C12Q2600/156

Abstract: The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.

Abstract translation: 本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否有获得不良药物反应风险的抗体，还是人类受试者是高反应者还是低反应者 他汀类药物或代谢物。 本发明提供了进一步的诊断方法和试剂盒，包括确定人受试者是否处于心血管疾病风险的抗体。 本发明还提供了多态序列和其他基因。

公开(公告)号：US20090208945A1

公开(公告)日：2009-08-20

申请号：US12097961

申请日：2006-12-19

Applicant: Stephan Schwers ,  Udo Stropp ,  Harald Kallabis ,  Andreas Schuppert ,  Rolf Burghaus ,  Christian Von Torne ,  Gerd Schmitz

Inventor： Stephan Schwers ,  Udo Stropp ,  Harald Kallabis ,  Andreas Schuppert ,  Rolf Burghaus ,  Christian Von Torne ,  Gerd Schmitz

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q1/42 ,  C12Q1/50 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/172 ,  G01N33/92

Abstract: The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a SADR gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat statin induced adverse drug reactions (SADR), the polynucleotide is selected from the group comprising: SEQ ID 1-35 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for SADR gene polypeptide and with or without the SADR gene promoter sequence.

Abstract translation: 本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否存在药物反应不利的风险的抗体。 本发明还提供了多态序列和其他基因。 本发明还涉及编码SADR基因多肽的分离的多核苷酸，其用于鉴定治疗剂并可用于制备治疗他汀类药物诱导的不良药物反应（SADR）的药物的方法中，所述多核苷酸选自SEQ ID No.1 -35具有等位基因变异，如包含在功能性周围的序列部分中所示，如SADR基因多肽的全长cDNA并具有或不具有SADR基因启动子序列。

公开(公告)号：US20090138204A1

公开(公告)日：2009-05-28

申请号：US12255695

申请日：2008-10-22

Applicant: Stephan Schwers ,  Harald Kallabis ,  Udo Stropp

Inventor： Stephan Schwers ,  Harald Kallabis ,  Udo Stropp

IPC: G01N33/48

CPC classification number: C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/6893 ,  G01N2800/32 ,  G01N2800/52

Abstract: Provided are diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Also provided are polymorphic sequences and other genes and isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response.

Abstract translation: 提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者是否在他汀类药物治疗后患有不良药物反应的风险或人类受试者是高反应者还是低反应者 或他汀类药物的代谢不良。 诊断方法和试剂盒包括确定人类受试者是否处于心血管疾病风险的抗体。 还提供了多态性序列和其他基因和编码表型相关（PA）基因多肽的分离的多核苷酸，其可用于鉴定治疗剂并用于制备治疗心血管疾病或影响药物应答的药物的方法。